Non Hodgkin Lymphoma Clinical Trial
NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
Patients will receive intravenous (IV) NKTR-255 in 21 or 28 day treatment cycles. During the Part 1 dose escalation portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab. After determination of the recommended Phase 2 dose (RP2D) of NKTR-255, NKTR-255 will be evaluated in Part 2. During the Part 2 dose expansion portion of the trial, patients will either receive NKTR-255 as monotherapy, NKTR-255 administered as a doublet with daratumumab subcutaneous (DARZALEX FASPRO TM), or NKTR-255 administered as a doublet with rituximab.
This is a Phase 1 study to evaluate safety and tolerability of NKTR-255 alone and in combination with daratumumab or rituximab.
NKTR-255 is a cytokine that is designed to regulate T and natural killer cell activation, proliferation and promote their anti-tumor effects.
This is a Phase 1, open-label, multi-center, dose escalation, dose expansion, safety follow-up, and survival follow-up of NKTR-255 as a single agent and NKTR-255 in combination with DARZALEX FASPRO TM or rituximab. Study treatment is defined as any investigational treatment(s) or marketed product(s), intended to be administered to a study patient according to the study enrollment.
Part 1 will enroll relapsed/refractory multiple myeloma (MM) and Non-Hodgkin's Lymphoma (NHL) patients. In Part 2, Cohort A will enroll NHL patients who have progressed on a chimeric antigen receptor T-cell (CAR-T) product, Cohort B will enroll MM patients who previously received daratumumab and other anti-CD38 therapies to receive NKTR-255 alone and/or in combination with daratumumab, and Cohort C will enroll indolent Non-Hodgkin's Lymphoma (iNHL) patients who previously received rituximab and other therapies to receive NKTR-255 alone and/or in combination with rituximab.
Key Inclusion Criteria:
Patients must have relapsed or refractory MM or NHL with no available therapies that would confer clinical benefit for their primary disease.
For MM patients, measurable relapsed or refractory MM as defined by the IMWG Criteria (Kumar, 2016) following treatment with at least 3 lines of therapy with no other available treatment that would confer benefit.
For NHL patients, measurable or detectable disease according to International Myeloma Working Group (IMWG) and the Lugano Classification. Extranodal NHL disease that is measurable by fluorodeoxyglucose-positron emission tomography (FDG-PET) imaging only is allowed.
Estimated glomerular filtration rate (eGFR) ≥ 40 mL/min/1.73 m2.
Eastern Cooperative Oncology Group (ECOG) performance status score ≤ 2
Patient has the following laboratory test results during Screening:
Absolute neutrophil count (ANC) or absolute granulocyte count (AGC) ≥ 1000/µL
Platelets ≥ 30,000/µL
Hemoglobin ≥ 8g/dL
Absolute lymphocytes ≥ 500/µL
Leukocytes ≥ 3000/µL
Patients are eligible who also meet all the following criteria in these cohorts of Part 2:
NKTR-255 Monotherapy NHL Group Only:
Patients with NHL who received a commercially approved CD19 CAR-T product and had PD. The first dose of NKTR-255 will be administered within 30 days of the PD.
NKTR-255 with Daratumumab MM Group Only :
Patients with MM must have had previous exposure to proteasome inhibitor, immunomodulatory agent (IMiD), and anti-CD38 therapy.
Patients who previously received daratumumab or other anti-CD38 therapies must have at least 3 months washout.
NKTR-255 with Rituximab Group iNHL Group Only:
Patients with relapsed or refractory iNHL who previously progressed during or following 1 or more prior systemic rituximab-containing (or another treatment with an anti-CD20 antibody-containing) regimens for lymphoma.
Key Exclusion Criteria:
Patients who have an active, known, or suspected autoimmune disease.
Any treatment-related neurotoxicity or cytokine release syndrome (CRS) prior to enrollment into the study should return to baseline before NKTR-255 treatment.
Active central nervous system (CNS) involvement with NHL.
Patients who have been previously treated with prior interleukin-2 or interleukin-15.
Patients who received daratumumab or other anti-CD38 therapies previously must have 3 months washout.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 13 Locations for this study
Goodyear Arizona, 85338, United States
Duarte California, 91010, United States
San Francisco California, 94143, United States
Tampa Florida, 33612, United States
Atlanta Georgia, 30322, United States
Ann Arbor Michigan, 48109, United States
Minneapolis Minnesota, 55455, United States
New York New York, 10065, United States
Valhalla New York, 10595, United States
Durham North Carolina, 27705, United States
Houston Texas, 77030, United States
Fairfax Virginia, 22031, United States
Seattle Washington, 98109, United States
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.